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An examination of deoxyadenosine 5'(a-thio)triphosphate as a
ligand to de®ne P2Y receptors and its selectivity as a low potency
partial agonist of the P2Y1 receptor
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1 The functional activity of deoxyadenosine 5'(a-thio)triphosphate (dATPaS) was assessed at the cloned
human P2Y1 receptor stably expressed in 1321N1 human astrocytoma cells and transiently expressed in
Cos-7 cells.
2 Cells expressing the receptor responded to adenine nucleotides with an increase in [3H]-inositol
phosphate accumulation. Half-maximal responses were obtained at approximately 30 nM for 2-
methylthioadenosine-5'-triphosphate (2MeSATP), 300 nM for dATPaS, and 1000 nM for adenosine 5'-
triphosphate (ATP). dATPaS produced a maximal response that was only 37+4% of that produced by
ATP or 2MeSATP. dATPaS also competitively antagonized the phospholipase C response to 2MeSATP
with a KB of 644+14 nM. Thus dATPaS acts as a low potency partial agonist at P2Y1 receptors.
3 The selectivity of dATPaS for P2Y1 receptors was determined by examining its capacity to activate
P2Y2, P2Y4 and P2Y6 receptors also stably expressed in 1321N1 cells. Although dATPaS was a partial
agonist at P2Y1 receptors it was a full agonist at P2Y2 receptors, albeit with a potency that was two
orders of magnitude lower than at P2Y1 receptors. No agonist or antagonist activity was observed at
P2Y4 and P2Y6 receptors.
4 Although [35S]-dATPaS bound to a relatively high density (ca 10 pmol mg71 protein) of binding sites
in membranes from 1321N1 or Cos-7 cells expressing the P2Y1 receptor, no dierence in the total density
of sites was observed between membranes from wild-type, empty vector-transfected, or P2Y1 receptor-
expressing cells. Moreover, adenine nucleotide analogues inhibited [35S]-dATPaS binding with an order
of potency that diered markedly from that for the accumulation of inositol phosphates in intact
transfected P2Y1 receptor-expressing cells. Saturation binding experiments demonstrated multiple anity
states for [35S]-dATPaS binding in wild-type Cos-7 cell membranes. These data from 1321N1 and Cos-7
cells suggest that cellular membranes exhibit a large number of high anity binding sites for [35S]-
dATPaS that are not related to P2Y receptor subtypes.
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Introduction
Extracellular receptors for adenine nucleosides and nucleotides
were initially divided into two families based on the relative
potencies of adenosine (P1-receptors) and adenosine 5'-tri-
phosphate (ATP; P2-receptors) in various tissue responses.
Recognition that methylxanthines are potent inhibitors of re-
sponses to adenosine (Sattin & Rall, 1970) prompted the de-
velopment of a series of antagonist molecules that have been
used to characterize and radiolabel several subtypes of P1 re-
ceptors.
Subtypes of P2-receptors (P2X and P2Y) were originally de-
®ned pharmacologically based on the relative potencies of 2-
methylthio-ATP (2MeSATP), ATP and a,b methylene-ATP in
contractile responses of a variety of peripheral tissues (Burn-
stock & Kennedy, 1985). In contrast to the situation with
adenosine receptors, the lack of selective, high anity ligands
for P2 receptors has prevented unambiguous identi®cation and
characterization of P2 receptor subtypes in intact tissues. The
recent molecular cloning of a number of P2X and P2Y re-
ceptor subtypes (the subscripted terms P2X and P2Y are used
here to designate receptor classes that have been de®ned
pharmacologically by Burnstock and Kennedy (1985) whereas
P2Xn and P2Yn (where n=1, 2, 3 . . .) refer to molecularly
de®ned P2 receptor subtypes) now provides the opportunity to
determine the potencies of various compounds at structurally
de®ned receptors.
With the exception of chain-extended 2-thioether deriva-
tives of ATP and ADP (Fischer et al., 1993), no P2Y re-
ceptor agonists have been found that exhibit potencies in
the range of concentrations, i.e. nanomolar, that conven-
tionally have been necessary for reliable receptor radioli-
gands. Further, molecules known to act as P2Y receptor
antagonists have been shown to do so with only micro-
molar anity. Thus, it is of interest that [35S]-2' deoxya-
denosine-5'-(a-thio)triphosphate ([35S]-dATPaS) has been
utilized recently in attempts to radiolabel selectively and
pharmacologically de®ne native P2Y receptors in brain tissue
and recombinant P2Y receptors expressed in cultured cells
(Simon et al., 1995a,b; Webb et al., 1996; Akbar et al.,
1996; Vallejo et al., 1996). It has been proposed that [35S]-
dATPaS exhibits high anity, speci®c binding to three
dierent putative P2-receptor subtypes (Simon et al., 1995a;
Webb et al., 1996; Akbar et al., 1996). Since the pharma-
cological activity of dATPaS has not been documented
previously, we have determined and compared both the
activity and the ligand binding characteristics of dATPaS at
the cloned human P2Y1 receptor. Our data are not con-
sistent with a selective, high anity interaction of dATPaS
with the human P2Y1 receptor and suggest that radioligand
binding of the compound is predominantly to endogenous
ATP-binding proteins that are distinct from the expressed
P2Y1 receptor.
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Methods
Expression of the human P2Y1 receptor
The molecular cloning of the human P2Y1 receptor has been
demonstrated previously (Schachter et al., 1996). The re-
ceptor was subcloned into the plasmid pcDNA3 with EcoR1
and Xho1 restriction sites and expressed in 1321N1 human
astrocytoma cells by the calcium phosphate precipitation
transfection method (Chen & Okayama, 1987). These cells
were utilized because they do not exhibit functional re-
sponses to agonists of any of the known P2Y receptors. All
of the experiments described here for the P2Y1 receptor in
1321N1 cells were performed in a stably expressing cell clone
(clone 6T) that showed the largest magnitude of functional
response to purinoceptor agonists among eleven clones ex-
amined.
The P2Y1 receptor also was expressed transiently in Cos-7
cells with Lipofectamine reagent (Gibco BRL). Optimized
conditions involved treating cells at approximately 70%
con¯uency in 100 mm plates with 21 ml of Lipofectamine
reagent and 210 ng of plasmid DNA in serum-free Dulbec-
co's modi®cation of Eagle's medium (DMEM) for 12 h.
Following readdition of serum for 12 h, the cells were wa-
shed and either grown in the 100 mm plates for two days
before harvest for membrane binding assays or split into 24
well plates for assay of inositol phosphate accumulation
48 h later.
Quantitation of inositol lipid hydrolysis
The presence and pharmacological selectivity of the P2Y1
receptor was assessed by quantitation of inositol lipid hy-
drolysis in response to purinoceptor agonists. Cells expres-
sing recombinant receptor were replated at a density of
16105 cells/well in 24 well plates and grown to con¯uence
(two to three days in culture) before the assay. The culture
medium was replaced 24 h before the assay with 200 ml of
serum-free, inositol-free DMEM supplemented with 0.4 mCi
[3H]-myo-inositol (20 Ci mmol71, American Radiolabeled
Chemicals). Drugs were added as 5X concentrated stocks in
50 ml of 250 mM HEPES, pH 7.3, containing 50 mM LiCl.
Incubations were stopped by rapidly aspirating the medium
and the cell lysate was applied directly to Dowex AG1-X8
columns for chromatographic isolation of inositol phos-
phates (Berridge et al., 1985). Assays were performed at
least three times in triplicate.
Membrane binding of [35S]-dATPaS
Membranes were prepared from 100 mm plates of transfected
or wild type cells either exactly as described (Simon et al.,
1995a; Webb et al., 1996) or with the following minor modi-
®cations. The freeze/thaw method for cell lysis used in the
previous studies was replaced by hypotonic swelling and
homogenization in 5 mM Tris, pH 7.4, containing 1 mM
EDTA, 1 mM EGTA, and protease inhibitors (100 mg ml71
bacitracin, 10 mg ml71 soy bean trypsin inhibitor, 10 mg ml71
aprotinin, 1 mM benzamidine and 0.1 mM phenylmethylsul-
phonyl ¯uoride). Following cell disruption with a Brinkman
Polytron (setting 5.5 for 10 s on ice) the membranes were
centrifuged at 25,0006 g and resuspended three times in 10 ml
of the above buer containing 50 mM Tris, pH 7.4 (buer A).
The pellets were gently resuspended each time in a hand-held
glass/glass homogenizer, replacing the practice of trituration
with a 22 gauge needle. Membranes were rapidly frozen and
stored at 7808C. Before assay the thawed membranes were
homogenized in a motor-driven glass/te¯on homogenizer. All
manipulations were performed rapidly with ice-cold solutions
and instruments. Direct comparison of the freeze/thaw/tri-
turation method and the alternative method described above
gave similar results, but use of the modi®ed method resulted in
greater reproducibility.
Binding assays were initiated by addition of 50 ml of
membranes (10 mg protein) to 100 ml of buer A containing
the radioligand with or without competing drug, giving a ®nal
concentration of 10 nM [35S]-dATPaS (0.15 mCi/assay adjusted
to 10 nM with unlabelled dATPaS). Following incubation for
60 min at room temperature with constant shaking, the assay
was terminated by rapidly adding 5 ml of ice-cold 20 mM Tris,
pH 7.4, and immediately ®ltering over glass ®bre ®lters
(Scheicher & Schuell #30) presoaked with 20 mM pyropho-
sphate, 20 mM Tris, pH 7.4. Filters were washed twice before
being dried and counted.
Materials
[35S]-dATPaS was obtained from Amersham. Unlabelled
dATPaS was from New England Nuclear. Lipofectamine re-
agent and cell culture media were from Gibco. [3H]-myo-ino-
sitol was from American Radiolabeled chemicals. Nucleotides
and HEPES buer were purchased from Boehringer Manheim.
Other reagents were from Sigma.
Results
Functional activity of dATPaS in 1321N1 cells
expressing the human P2Y1 receptor
Although [35S]-dATPaS is purported to radiolabel the P2Y1
receptor and other putative P2Y receptors (Simon et al.,
1995a,b; Webb et al., 1996; Akbar et al., 1996; Vallejo et al.,
1996), the pharmacological activity of the compound at P2Y
receptors has not, to our knowledge, been de®ned. Therefore,
we have examined the activity of dATPaS at the recombinant
human P2Y1 receptor. We previously characterized the phar-
macological selectivity of the human P2Y1 receptor expressed
in 1321N1 cells by examining the phospholipase C response to
approximately 20 adenine nucleotides (Schachter et al., 1996).
Most of these nucleotides produced the same maximal re-
sponse, despite considerable dierences in EC50 values. Here
we compared the eect of dATPaS to those of 2MeSATP and
ATP, which appeared to act as full agonists in 1321N1-hP2Y1
cells (Schachter et al., 1996). As presented in Figure 1, dATPaS
promoted inositol lipid hydrolysis, but the maximal eect





























Figure 1 Inositol phosphate accumulation in 1321N1 cells stably
transfected with the human P2Y1 receptor. A stable transfectant was
clonally selected for purinergic responsiveness and inositol phosphate
accumulation was assessed after a 10 min incubation with 2MeSATP
(*), ATP (~) or dATPaS (&). Data for each nucleotide
concentration (mean with s.e.mean (vertical lines) of three experi-
ments performed in triplicate) are normalized to the inositol
phosphate response of 3 mM 2MeSATP (4 ± 6 fold above the blank
or basal level) and are shown with the basal value (usually about
2000 c.p.m.) subtracted.
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either ATP or 2MeSATP. Several possible explanations were
considered for the smaller maximal response of dATPaS. The
time course of inositol phosphate accumulation in the presence
of a maximally eective concentration of dATPaS was a
constant fraction of that of 2MeSATP at all times of incuba-
tion examined (Figure 2). Additionally, preincubation of cells
with dATPaS for 20 min did not alter the subsequent response
to a supramaximal concentration of 2MeSATP. Thus,
dATPaS did not appear to desensitize rapidly or nonspeci®-
cally inhibit the activity of the P2Y1 receptor. Similar results
were obtained with 1321N1 cells expressing the recombinant
turkey P2Y1 receptor (data not shown), indicating that the low
potency and partial agonist behaviour of dATPaS is not sim-
ply a re¯ection of dierences in avian versus mammalian
homologues of the P2Y1 receptor.
To determine whether dATPaS exhibited the characteristics
of a competitive antagonist of the P2Y1 receptor, we generated
concentration-eect curves for dATPaS in the presence of
several concentrations of 2MeSATP (Figure 3a). dATPaS
produced a concentration-dependent inhibition of 2MeSATP-
stimulated inositol phosphate accumulation down to the level
induced by the partial agonist alone. Concentration-eect
curves also were established for 2MeSATP in the presence of
various concentrations of dATPaS (Figure 3b). Increasing
concentrations of dATPaS caused a shift to the right of the
agonist concentration-response curve for 2MeSATP. Analysis
of these data according to the method of Schild (1947) gave a
KB value of 644+14 nM for dATPaS as a P2Y1 receptor an-
tagonist (Figure 3c).
To establish the selectivity of dATPaS among other G
protein-coupled P2Y receptors, we examined its capacity to
activate P2Y2, P2Y4 and P2Y6 receptors, each stably expressed
in 1321N1 cells. dATPaS was fully ecacious in activating the
human P2Y2 receptor, but did so with low potency
(EC50=23.1+3.6 mM, Figure 4a) compared with the potency
of ATP or UTP (230 or 140 nM, (Lazarowski et al., 1995)) in
the same P2Y2 receptor-expressing cells. Neither agonist nor
antagonist activity was observed with dATPaS at the P2Y4 or
P2Y6 receptors (Figure 4b) or at a P2Y receptor on C6 rat
glioma cells (Boyer et al., 1993) that couples to the inhibition
of adenylyl cyclase (not shown).
Radioligand binding of [35S]-dATPaS to membranes
from transfected cells
In light of the application of [35S]-dATPaS in studies designed
to radiolabel the P2Y1 receptor (Simon et al., 1995a), and two
other putative P2 receptors (Webb et al., 1996; Akbar et al.,
1996), we carried out similar binding assays with membranes
from 1321N1 cells engineered to express stably the P2Y1 re-
ceptor. Although a high level of [35S]-dATPaS binding was
observed, similar amounts of total [35S]-dATPaS binding oc-
curred with membranes obtained from both wild type 1321N1
cells and from 1321N1 cells expressing high concentrations of
the P2Y1 receptor (based on the marked inositol phosphate
response of these cells to 2MeSATP). The binding of [35S]-
dATPaS to membranes from 1321N1-hP2Y1 cells was
inhibited by adenine nucleotide analogues, but the order of
potency (2',3'- dideoxyATP4ATP4 2MeSATP5ADP4
2MeSADP; Figure 5) was markedly dierent from the order of
potency of these compounds for activation of inositol lipid
hydrolysis (2MeSADP42MeSATP4ADP4ATP442',3'-di-
deoxyATP; see Table 1). Additionally, two compounds that
are competitive antagonists of the P2Y1 receptor at low mi-
cromolar concentrations, PPADS (pyridoxalphosphate-6-azo-
phenyl - 2',4' - disulphonic acid) and adenosine - 3',5' - bis-
phosphate (Boyer et al., 1994; 1996), only inhibited [35S]-
dATPaS binding at millimolar concentrations. Thus, no evi-
dence for radiolabelling of P2Y1 receptors was observed with
membranes obtained from 1321N1-hP2Y1 cells.
Several of the previously published studies of [35S]-dATPaS
binding were performed in transiently transfected Cos-7 cells




























Figure 2 Time course of inositol phosphate accumulation in the
presence of dATPaS and 2MeSATP. LiCl (10 mM ®nal concentra-
tion) was added simultaneously with 10 mM dATPaS (*) or 30 mM
2MeSATP (&) to 1321N1-hP2Y1 cells. A third set of cells was
preincubated with 10 mM dATPaS for 20 min in the absence of LiCl
before the addition of 30 mM 2MeSATP plus LiCl (&). The basal (or
blank) value did not change over the time of the assay and was
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Figure 3 Antagonist activity of dATPaS at the human P2Y1 receptor. Inositol phosphate accumulation in 1321N1-hP2Y1 cells was
determined in the presence of various concentrations of dATPaS and 2MeSATP alone and in combination. (a) Concentration-
response pro®le of dATPS in the absence (&) or presence of 40 nM (~), 100 nM (*) or 400 nM (^) 2MeSATP. (b) Concentration-
response pro®le of 2MeSATP in the absence (&), or presence of 0.1 (*), 0.3 (~), 1 (~), 3 (^), 10 (^) or 30 mM dATPaS (*). (c)
Schild plot of the data from (b). The average of three such plots gave a Ki value of 644+14 nM and a slope of 1.1+0.15.
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Therefore, we also carried out [35S]-dATPaS binding experi-
ments in Cos-7 cells transfected with the human P2Y1 receptor.
Control or vector-transfected cells did not respond to dATPaS,
2MeSADP or 2MeSATP with an increase of inositol phos-
phate accumulation. However, both ATP and UTP promoted
inositol phosphate accumulation in a nonadditive manner
(Figure 6a), suggesting the presence in Cos-7 cells of an en-
dogenous nucleotide receptor. The response to UTP (or ATP,
data not shown) was not aected by the presence of 30 mM
dATPaS (Figure 6b). Transfection of Cos-7 cells with DNA
encoding the human P2Y1 receptor conferred a responsiveness
to 2MeSADP, 2MeSATP and dATPaS (Figure 7a). As was the
case with 1321N1 cells expressing the P2Y1 receptor, dATPaS
elicited only a fraction of the response observed for 2MeSADP
and 2MeSATP. The response to ATP in P2Y1 receptor-ex-
pressing Cos-7 cells was approximately twice as large as the
2MeSATP response, due to the additive eects of ATP at the
transfected P2Y1 receptor and the endogenous nucleotide re-
ceptor (Figure 7a).
Radioligand binding assays were carried out with [35S]-
dATPaS in membranes prepared from P2Y1 receptor-trans-
fected Cos-7 cells. As with membranes from 1321N1 cells, no
dierence in total [35S]-dATPaS binding was observed between
membranes from wild type and P2Y1 receptor-expressing Cos-
7 cells. The order of potency for the inhibition of [35S]-dATPaS
binding by adenine nucleotides was markedly dierent from
that for the stimulation of inositol phosphate accumulation in
intact cells (compare Figure 7a and b), but was not dierent
from the order of potency for the inhibition of binding to
membranes from nontransfected Cos-7 cells (Figure 7c). [35S]-
dATPaS binding in membranes from non-transfected Cos-7
cells was also inhibited by suramin and reactive blue-2, which
have been commonly used to suggest the involvement of pur-
inoceptors (Table 2). Since Cos-7 cells express an endogenous
PLC-coupled nucleotide receptor that is sensitive to both uri-
dine 5'-triphosphate (UTP) and ATP (Figure 5a), the possi-
bility that this receptor is responsible for the binding of [35S]-
dATPaS was considered. However, the endogenous nucleotide
receptor of Cos-7 cells was neither activated nor antagonized
by dATPaS (Figure 5), and much higher concentrations of
UTP were necessary to inhibit [35S]-dATPaS binding than to
stimulate inositol phosphate accumulation (see Table 2).
The previous studies of [35S]-dATPaS binding utilized a
narrow range of radioligand concentrations and concluded
that binding was to a single population of sites in transfected
Cos-7 membranes (Simon et al., 1995a; Webb et al., 1996;






















































Basal           UTP               Basal          UDP
1321N1-P2Y4 1321N1-P2Y6
Figure 4 Inositol phosphate accumulation in 1321N1 cells expres-
sing the P2Y2, P2Y4 or P2Y6 receptors. (a) The response of 1321N1-
hP2Y2 cells to dATPaS is expressed as a percentage of the maximal
response to 10 mM UTP. (b) The eects of 30 mM dATPaS alone or in
the presence of 2 mM UTP (in P2Y4-expressing cells) or to 0.5 mM
UDP (in P2Y6-expressing cells) were quantitated. These uridine
nucleotide concentrations elicited 60 ± 65% of the maximal response
for P2Y4 or P2Y6 receptor-expressing cells. Values shown are the
mean+s.e.mean in the absence (open column) or presence (hatched

























Figure 5 Inhibition of [35S]-dATPaS binding to membranes from
1321N1-hP2Y1 cells. Membranes prepared from 1321N1-hP2Y1 cells
were incubated with 10 nM [35S]-dATPaS and the indicated
concentrations of competing drug as described in Methods. Data
shown are for 2'3'-dideoxy ATP (~), ATP (*), ADP (*),
2MeSADP (^) and PPADS (&).
Table 1 Comparison of EC50 values for inositol lipid
hydrolysis with IC50 values for the inhibition of [
35S]-
dATPaS binding in 1321N1-hP2Y1 cells
Inositol phosphates Ligand binding



























EC50 values (in nanomolar) are shown in the middle column
for the stimulation of inositol phosphate accumulation by
adenine nucleotides in 1321N1 cells stably transfected with
the human P2Y1 receptor. IC50 values are shown in the
righthand column for inhibition of [35S]-dATPaS binding in
membranes from these cells. Ki values for two P2Y1 receptor
antagonists were also compared with their IC50 values for
inhibition of binding.
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carried out over a wider range of ligand concentrations were
not consistent with binding of [35S]-dATPaS to a single po-
pulation of sites in membranes from control (Figure 8) or P2Y1
receptor-transfected (data not shown) cells. These data are
consistent with the binding of [35S]-dATPaS to a number of
sites on Cos-7 membranes which are distinct from the nu-
cleotide binding site of the P2Y1 receptor.
Discussion
Stable expression of the cloned human P2Y1 receptor in
1321N1 human astrocytoma cells confers an inositol phos-
phate response to a broad range of adenine nucleotides
(Schachter et al., 1996). dATPaS exhibited the properties of a
partial agonist/competitive antagonist at the expressed P2Y1
receptor, and the KB value derived in experiments designed to
examine the capacity of dATPaS to antagonize competitively
the eects of 2MeSATP was in the range of KB values pre-
viously obtained for suramin, PPADS and reactive blue 2 at
the P2Y1 receptor (Boyer et al., 1994). Although [
35S]-dATPaS
bound with relatively high anity to membranes prepared
from 1321N1 and Cos-7 cells stably or transiently expressing
the human P2Y1 receptor, the order of potency of adenine
nucleotide analogues and P2 receptor antagonists for inhibi-
tion of radioligand binding was markedly dierent from the
order of potency for stimulation of inositol phosphate accu-
mulation. Moreover, a similar density of [35S]-dATPaS binding
sites and similar pharmacological selectivity for inhibition of
binding was observed in nontransfected cells which did not
exhibit an inositol phosphate response to P2Y1 receptor-se-
lective agonists.
The relatively high KB value of dATPaS (644 nM by
Schild analysis) suggests that this molecule does not exhibit
suciently high anity at P2Y1 receptors to be utilized in a
radioligand binding assay for this receptor. [35S]-dATPaS is
unlikely to remain P2Y1 receptor-associated during proces-
sing of samples by membrane ®ltration, even in the absence




















































Basal            0.3                1              10
[UTP] µM
Figure 6 Lack of activity of dATPaS at the endogenous nucleotide
receptor in wild type Cos-7 cells. (a) Inositol phosphate accumulation
in wild type Cos-7 cells was measured in response to dATPaS (~),
2MeSADP (&), 2MeSATP (&), ATP (*), UTP (^) and to ATP in
the presence of 10 mM UTP (^). (b) UTP-stimulated inositol
phosphate accumulation was assessed in wild-type Cos-7 cells in
the absence (open columns) or presence (hatched columns) of 30 mM
dATPaS. Data in (b) are shown without subtraction of basal inositol
phosphate accumulation. Data are shown as the mean+s.e.mean of
three experiments performed in triplicate.
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Figure 7 Comparison of functional response with inhibition of
radioligand binding in transiently transfected Cos-7 cells. (a) Inositol
phosphate accumulation in transiently transfected Cos-7 cells. Results
are expressed as the percentage of the maximal response to
2MeSATP (3 fold above basal) and are shown with basal inositol
phosphate accumulation subtracted. Activities are shown for
2MeSADP (&), 2MeSATP (&), ATP (*) and dATPaS (~). (b)
Inhibition of [35S]-dATPaS binding to membranes from transiently
transfected Cos-7 cells. Drugs and symbols are as in (a). (c)
Inhibition of [35S]-dATPaS binding to membranes from non-
transfected Cos-7 cells (symbols as in (a)).
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of binding to other proteins. Moreover, membranes from
wild-type Cos-7 and 1321N1 cells bound [35S]-dATPaS with
high capacity and in the low nanomolar range of anities.
dATPaS is not a general ligand for P2Y receptors since
functional studies indicated that this compound is two or-
ders of magnitude less potent at the P2Y2 receptor and has
no agonist or antagonist activity at the P2Y4 or P2Y6 re-
ceptors or at an adenylyl cyclase-coupled P2Y receptor in
C6 glioma cells.
Adenine nucleotide analogues including [35S]-ATPaS
(Keppens et al., 1990), [35S]-ADPbS (Cooper et al., 1989),
[35S]-ATPgS and [a-32P]-ATP (Motte et al., 1996), have been
used in other attempts to radiolabel P2Y receptors. We have
previously questioned the validity of our initial contention
(Cooper et al., 1989) that [35S]-ADPbS might be utilized to
radiolabel the turkey erythrocyte P2Y receptor (Harden et
al., 1995). Based on a biphasic displacement curve for in-
hibition of binding by 2MeSATP, Motte et al. (1996) have
concluded that at least two thirds of the binding sites for
[35S]-ATPgS and [a-32P]-ATP on bovine aortic endothelial
membranes are not P2Y receptors. In the same study,
2MeSATP did not displace any of the radioligand binding
to intact cells, suggesting that cell surface P2Y receptors
represent, at most, a minimal percentage of the total cellular
adenine nucleotide ligand binding sites. This conclusion is
consistent with the extraordinary number of binding sites
identi®ed by [35S]-ATPaS binding in guinea-pig and rabbit
liver (47 and 71 pmol mg71, respectively, (Keppens et al.,
1990)) and by [35S]-dATPaS in membranes from rat brain
(39 pmol mg71, (Simon et al., 1995b)) or rabbit gastric
glands (16.8 pmol mg71, (Vallejo et al., 1996)).
A member of the G protein-coupled class of receptors with
32 to 36% homology to other P2Y receptors has been cloned
from a cDNA library prepared from activated chick T-lym-
phocytes (Kaplan et al., 1993). This orphan receptor, desig-
nated 6H1, recently was suggested to be a P2Y receptor (the
P2Y5 receptor) based on the fact that [
35S]-dATPaS bound to
membranes from Cos-7 cells transfected with DNA encoding
this receptor (Webb et al., 1996). However, no binding data
have been obtained for membranes from wild-type cells, and
no functional responses of this receptor to dATPaS, ATP or
other adenine nucleotide analogues have been found. Our re-
sults with [35S]-dATPaS binding indicate that this molecule
does not exhibit the properties necessary for use as a speci®c
radioligand for P2Y receptors. Moreover, in membranes from
non-transfected Cos-7 cells we observed that [35S]-dATPaS
binding was inhibited by adenine nucleotide analogues with
similar potencies to those obtained for membranes from 6H1
receptor-transfected Cos-7 cells. These results do not support
the contention that the 6H1 receptor is a P2Y receptor sub-
type.
Kunapuli and coworkers (Akbar et al., 1996) have cloned a
G protein-coupled receptor that is 24 ± 30% homologous with
G protein-coupled P2Y receptors and have proposed this to be
a P2Y7 receptor based primarily on the binding of [
35S]-
dATPaS to membranes from transfected Cos-7 cells. No
comparative binding with membranes from wild-type cells was
obtained. Moreover, the overall pharmacological selectivity
that was observed in [35S]-dATPaS binding assays with mem-
branes from receptor-transfected Cos-7 cells (Akbar et al.,
1996) was very similar to that observed here with membranes
from wild-type Cos-7 cells. A small inositol phosphate re-
sponse to a single concentration of ATP was found for Cos-7
cells transfected with cDNA for the putative P2Y7 receptor
(Akbar et al., 1996). Since we consistently observed an inositol
phosphate response to ATP in wild type Cos-7 cells, a detailed
pharmacological analysis will be necessary to dierentiate any
response of a heterologously expressed putative P2Y receptor
from that of the endogenous nucleotide receptor in Cos-7 cells.
The introduction of a compound that could be used to
identify and quantify selectively one or more P2Y receptor
subtypes would be of considerable use to the P2 receptor sig-
nalling ®eld. Ideally, such a compound would exhibit nano-
molar anity and selectivity for P2 receptors as well as be
resistant to nucleotidase activity. [35S]-dATPaS is one of a
group of radiolabelled purine nucleotide analogues that does
not appear to ful®ll these criteria. However, this molecule is a
partial agonist/competitive antagonist at the P2Y1 receptor.
This antagonist activity, together with its relative selectivity for
Table 2 Comparison of EC50 values for inositol lipids hydrolysis with IC50 values for the inhibition of [
35S]-dATPaS binding in
transfected and wild type Cos-7 cells
Wild type Cos-7 hP2Y1 Cos-7
Inositol phosphates Binding Inositol phosphates Binding















































































Figure 8 Saturation isotherm for [35S]-dATPaS binding to wild-type
Cos-7 membranes. Membranes were incubated with increasing
amounts of unlabelled dATPaS in the presence of a ®xed
concentration of radiolabel, followed by calculation of bound and
free concentrations. Nonspeci®c binding (approximately 5% of total
binding) was de®ned as the amount of [35S]-dATPaS binding
remaining in the presence of 1074 M 2MeSATP and this value was
subtracted from the total radioligand bound at each concentration of
dATPaS before calculation of bound and free concentrations. The
inset shows a Scatchard replot of the data.
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the P2Y1 receptor, support the idea that derivatives of dATPaS
might be synthesized as selective high anity P2Y1 receptor
antagonists.
This work was supported by USPHS grants GM 38213, GM 29536,
and HL 32322, and by a grant from INSPIRE Pharmaceuticals.
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